Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 5/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3237316 | 0.94 | CHRNB2 (0.60) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL28167716 | 0.85 | RIPK1 (0.49) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL5660732 | 0.81 | CYP19A1 (0.43) | CHRNA7ALDH1A1CYP2D6CYP2C9TSHR | |
| SCHEMBL9274951 | 0.79 | TP53 (0.55) | ALDH1A1RIPK1HSD11B1SLC18A3CYP2D6 | |
| SCHEMBL443829 | 0.77 | ALDH1A1 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL17414358 | 0.77 | CHRNB2 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL16130578 | 0.76 | CHRNB2 (0.89) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Hydrochloric Acid SCHEMBL28855195 | 0.76 | CHRNB2 (0.58) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL6839621 | 0.76 | CHRNB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL2251648 | 0.76 | CHRNB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114008526-B | Curable resin composition, method for producing curable resin composition, cured film, laminate, method for producing cured film, and semiconductor device | 富士胶片株式会社 | 2024-11-08 | — | — | CN | disclosed |
| CN-113939286-A | Sustained release pharmaceutical formulation | 道格拉斯制药有限公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-111630026-A | Sustained release pharmaceutical formulations and methods of treatment | 道格拉斯制药有限公司 | 2020-09-04 | — | — | CN | disclosed |
| US-9878986-B2 | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-01-30 | — | — | US | disclosed |
| CN-105358556-B | New compound for selective histone deacetylase inhibitor and the pharmaceutical composition comprising it | 株式会社钟根堂 | 2018-01-02 | — | — | CN | disclosed |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2016-03-24 | — | — | US | disclosed |
| EP-2991982-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2016-03-09 | — | — | EP | disclosed |
| CN-105358556-A | Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARM CORP | 2016-02-24 | — | — | CN | disclosed |
| WO-2014178606-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-11-06 | — | — | WO | disclosed |
| CN-1805944-A | Cyclic hydroxylamine as psychoactive compounds | BTG INT LTD (GB) | 2006-07-19 | — | — | CN | disclosed |
| US-20060142286-A1 | Cyclic hydroxylamine as psychoactive compounds | BTG INTERNATIONAL LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| EP-1631557-A1 | CYCLIC HYDROXYLAMINE AS PSYCHOACTIVE COMPOUNDS | BTG INTERNATIONAL LIMITED (GB) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004111021-A1 | CYCLIC HYDROXYLAMINE AS PSYCHOACTIVE COMPOUNDS | BTG INTERNATIONAL LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004111021-A1 | CYCLIC HYDROXYLAMINE AS PSYCHOACTIVE COMPOUNDS | BTG INTERNATIONAL LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| EP-0937064-B1 | SUBSTITUTED OXIMES DERIVATIVES USEFUL AS NEUROKININ ANTAGONISTS | SCHERING CORP (US) | 2002-12-11 | — | — | EP | disclosed |
| EP-0937064-A1 | SUBSTITUTED OXIMES DERIVATIVES USEFUL AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1999-08-25 | — | — | EP | disclosed |
| CN-1182068-A | Process for separation of mixture of enantiomers | DSM NV (NL) | 1998-05-20 | — | — | CN | disclosed |
| WO-1998018785-A1 | SUBSTITUTED OXIMES DERIVATIVES USEFUL AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-05-07 | — | — | WO | disclosed |
| US-5688960-A | ANTIHISTANINE, RESPIRATORY SYSTEM DISORDERS, ANTIINFLAMMATORY AGENTS, GASTROINTESTINAL DISORDERS | SCHERING CORPORATION (US) | 1997-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC5, HDAC4 | CHRNB2 2607/4885CHRNB4 2514/4885CHRNA3 2119/4885 |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC5, HDAC4 | CHRNB2 2607/4885CHRNB4 2514/4885CHRNA3 2119/4885 |
| US-20060142286-A1 | Cyclic hydroxylamine as psychoactive compounds | HTR1A, HTR2C, OPRM1 | CHRNB2 220/4885CHRNB4 201/4885CHRNA3 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.